This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
GEHC Launches AI-Powered Vivid Pioneer Cardiac Ultrasound System
by Zacks Equity Research
GE HealthCare's Vivid Pioneer, cleared by CE Mark and FDA, brings AI-powered speed, precision and efficiency to cardiac imaging.
BSXNegative Net Change WSTPositive Net Change MEDPPositive Net Change GEHCPositive Net Change
medical medical-devices
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
ABTPositive Net Change AMGNPositive Net Change MDTPositive Net Change SYKPositive Net Change DXCMPositive Net Change ABBVPositive Net Change
biotechnology biotechs healthcare medical medical-devices robotics
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
by Ahan Chakraborty
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
by Zacks Equity Research
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
ALNYNegative Net Change RHHBYNegative Net Change CRMDPositive Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
by Zacks Equity Research
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
BIIBNegative Net Change LLYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
Charles River Stock May Benefit From Joining EASYGEN Consortium
by Zacks Equity Research
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
MASINegative Net Change CRLPositive Net Change PAHCNegative Net Change NVSTNegative Net Change
medical medical-devices
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
by Zacks Equity Research
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
MASINegative Net Change BIOPositive Net Change PAHCNegative Net Change NVSTNegative Net Change
medical medical-devices
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
by Zacks Equity Research
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
ABTPositive Net Change PAHCNegative Net Change MEDPPositive Net Change NVSTNegative Net Change
medical
FDA Identifies ICU Medical's Plum Duo Recall as Serious Type
by Zacks Equity Research
ICUI faces an FDA recall of its Plum Duo Infusion System over software flaws, though devices remain in use, pending fixes.
ICUIPositive Net Change WSTPositive Net Change MEDPPositive Net Change CGCNegative Net Change
medical medical-devices
Do Options Traders Know Something About Exelixis Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to EXEL stock based on the movements in the options market lately.
EXELNegative Net Change
medical
Is it Time to Hold on to Community Health Systems Stock?
by Zacks Equity Research
CYH benefits from rising occupancy, higher revenue per admission, and business streamlining, supporting its case as a stock to retain in your portfolio.
THCNegative Net Change CYHNegative Net Change EHCNegative Net Change
medical
Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?
by Zacks Equity Research
Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.
UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change
insurance medical pharmaceuticals
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
BSXNegative Net Change WSTPositive Net Change MEDPPositive Net Change TMDXNegative Net Change
medical medical-devices
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
PFEPositive Net Change MRNANegative Net Change BYDNegative Net Change NVAXNegative Net Change SCVLNegative Net Change
consumer-discretionary medical pharmaceuticals retail
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
by Zacks Equity Research
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
JNJPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
by Zacks Equity Research
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
CRMDPositive Net Change KNSANegative Net Change OTLKNegative Net Change PHARPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
by Sridatri Sarkar
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
ABTPositive Net Change EWPositive Net Change
medical
COO Q3 Earnings Beat, 2025 Sales Outlook Lowered, Stock Down
by Zacks Equity Research
Cooper Companies beats on Q3 earnings with 15% EPS growth, but revenue weakness and a trimmed 2025 outlook send shares tumbling.
BSXNegative Net Change COOPositive Net Change WSTPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
Here's Why You Should Add CLOV Stock to Your Portfolio Now
by Zacks Equity Research
Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.
BSXNegative Net Change WSTPositive Net Change MEDPPositive Net Change CLOVNegative Net Change
medical medical-devices
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run. Stocks like POST, MD, NVST and ZION are seeing price strength, and the momentum is likely to continue.
ZIONPositive Net Change MDPositive Net Change POSTPositive Net Change NVSTNegative Net Change
consumer-staples finance medical
Cannabis Stock VRNOF Soars 178% in a Month: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Verano's stock has surged 178% in a month on reform hopes, but pricing pressure and stiff competition test its momentum.
ACBNegative Net Change GTBIFNegative Net Change VRNOFPositive Net Change CURLFNegative Net Change
marijuana medical
The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?
by Moumi Mondal
HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.
BSXNegative Net Change HOLXPositive Net Change QGENPositive Net Change
medical medical-devices
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
by Zacks Equity Research
A posts fiscal Q3 earnings and revenue beats, with double-digit sales growth and upbeat guidance lifting shares.
APositive Net Change PAHCNegative Net Change SNDXPositive Net Change ASTHPositive Net Change
earnings medical medical-devices
HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups
by Zacks Equity Research
Humana teams up with Vori Health, HOPCo and TailorCare to expand value-based musculoskeletal care for Medicare Advantage members.
HUMPositive Net Change THCNegative Net Change AVDLPositive Net Change INFUPositive Net Change
insurance medical smart-health
Are Options Traders Betting on a Big Move in Becton Dickinson Stock?
by Zacks Equity Research
Investors need to pay close attention to Becton Dickinson stock based on the movements in the options market lately.
BDXPositive Net Change
medical medical-devices